Skip to content
Catalyst

PapersPMID:42942425

Lactobacillus rhamnosus Lysate for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial.

Medicina (Kaunas, Lithuania)2026The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, moderate evidenceno difference foundAlanine aminotransferase
  2. Finding, moderate evidenceno difference foundAspartate aminotransferase
Study, every finding
RCT · 3 months
Dose studied, every finding
100 mg twice daily for 12 weeks, then 3 months follow-up without treatment
Population, every finding
Adults aged 18-70 with MASLD (BMI 25-39.9, FLI >60); standard lifestyle-modification programme and counselling in both arms; between-group time-by-treatment interaction over 6 months

No finding here moved its endpoint.

Study record

Design
randomised controlled trial
Species
human
Population
Adults aged 18-70 with MASLD (fatty liver index above 60, BMI 25-39.9 kg/m2) at the Kyiv City Clinical Endocrinology Centre, Ukraine
Participants
52
Comparator
placebo
Duration
84 days
Endpoints measured
35